Overview

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir